drugset / Trial / NCT05113459
Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）
NaSingle-groupOpen-labelTreatment
Summary
This trial is a multi-center, open, single-arm, superior phase II clinical study.
Timeline
- Start
- 2021-12-18
- Primary completion
- 2023-12-18
- Completion
- 2024-06-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Disitamab Vedotin | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |